Ritonavir
USP/1604803 - United States Pharmacopeia (USP) Reference Standard
Synonym: 1,3-
CAS Number: 155213-67-5
Empirical Formula (Hill Notation): C37H48N6O5S2
Molecular Weight: 720.94
Linear Formula: C37H48N6O5S2
Product Type: Chemical
agency | USP |
API family | ritonavir |
application(s) | pharmaceutical (small molecule) |
biological source | synthetic |
color | white to tan |
form | powder |
format | neat |
grade | pharmaceutical primary standard |
InChI | 1S/C37H48N6O5S2/c1-24(2)3 |
InChI key | NCDNCNXCDXHOMX-XGKFQTDJSA |
manufacturer/tradename | USP |
packaging | pkg of 200 mg |
solubility | acetonitrile: slightly soluble |
ethanol: freely soluble | |
methanol: freely soluble | |
methylene chloride: freely soluble | |
water: practically insoluble | |
storage condition | protect from light |
vapor pressure | <0.0000001 kPa ( 25 °C) |
Analysis Note: | These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
Application: | Ritonavir USP reference standard suitable for use in specified USP compendial tests and assays. Also used to prepare standard, standard stock, identification, and standard working solution for assay, impurity analysis, and performance test according to the given below monographs of United States Pharmacopeia (USP): • Lopinavir and Ritonavir Tablets • Ritonavir Tablets • Ritonavir • Lopinavir and Ritonavir Oral Solution |
General description: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. Ritonavir belongs to the group of protease inhibitors that are widely used in combination with other drugs in the prevention of HIV. Its mode of action involves binding to the active site of the protease enzyme and preventing the further maturation of new viral particles. |
Other Notes: | Sales restrictions may apply. |
Symbol | GHS07 |
Signal word | Warning |
Hazard statements | H302 + H312 + H332 |
Precautionary statements | P261 - P280 - P301 + P312 + P330 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
UNSPSC | 41116107 |